Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Immunotherapy Combined With Chemotherapy in Sinonasal Mucosal Malignant Melanoma
NCT07614828Phase 2Withdrawn
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Sinonasal Mucosal Malignant Melanoma (SNMM), sponsored by Eye and ENT Hospital of Fudan University. Planned start Jun 2023; status: withdrawn.
02
Drugs
toripalimab
03
Conditions
Sinonasal Mucosal Malignant Melanoma (SNMM)
Beyond the preview
Go deeper on NCT07614828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614828.